Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)?

New drug developments in CF make this an exciting time to be involved in trials. Nearly 100 drugs are in the pipeline, including multiple cystic fibrosis transmembrane conductance regulator (CFTR) modulators [1], molecules restoring function of the defective CFTR protein rather than targeting symptoms and complications. Positive data from modulator trials have been widely discussed within the UK CF community, but post-approval funding has frequently required complex and time-consuming negotiation.

Source: Journal of Cystic Fibrosis - April 16, 2021 Category: Respiratory Medicine Authors: R. Dobra, G. Davies, K. Pike, C. Strassle, L. Allen, R. Brendell, K. Brownlee, S.B. Carr, N.J. Simmonds, J.C. Davies, London Network of Clinical Trials Accelerator Platform sites and affiliates Tags: Original Article Source Type: research